{"id":"W4396590627","doi":"10.1158/1538-7445.sabcs23-lbo1-04","title":"Abstract LBO1-04: Primary results from a phase 2a study of zanidatamab (zani) + palbociclib (palbo) + fulvestrant (fulv) in HER2+/HR+ metastatic breast cancer (mBC)","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre; Baker Hughes (Canada); Health Sciences Centre; Zymeworks (Canada); Ottawa Hospital; Jewish General Hospital","funders":"","keywords":"Palbociclib; Fulvestrant; Metastatic breast cancer; Medicine; Oncology; Internal medicine; Breast cancer; Cancer; Gynecology; Estrogen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002525797,0.001496591,0.001994279,0.0004728044,0.0005502467,0.001377464,0.001017807,0.001152137,0.008595483],"category_scores_gemma":[0.001170367,0.0005251103,0.001142669,0.0005451688,0.0007202922,0.0006868427,0.000465251,0.003246886,0.002722918],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001247632,"about_ca_system_score_gemma":0.002430727,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001666276,"about_ca_topic_score_gemma":0.00451054,"domain_scores_codex":[0.9993131,0.0003223042,0.00004323636,0.00009276572,0.0001143286,0.00011418],"domain_scores_gemma":[0.9991392,0.0001339064,0.0001785108,0.00006664453,0.00009013342,0.0003914731],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6520921,0.06875665,0.01966983,0.003290904,0.00373994,0.0005079522,0.0002504803,0.002596359,0.06361949,0.0004202338,0.03278879,0.1522673],"study_design_scores_gemma":[0.5048826,0.3914699,0.06304268,0.0002902828,0.003964152,0.0009497724,0.0001554827,0.001659199,0.01175274,0.0005198743,0.0212238,0.00008959705],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9333511,0.01319424,0.001874485,0.001847228,0.0002586078,0.008822983,0.02842425,0.0004981977,0.0117289],"genre_scores_gemma":[0.9365229,0.00498143,0.002775774,0.002702757,0.0003161331,0.003890709,0.04003531,0.0001376278,0.008637296],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008595483,"threshold_uncertainty_score":0.02875477,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1094288892429852,"score_gpt":0.4624104369764118,"score_spread":0.3529815477334266,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}